SEC Company Response from ARTELO BIOSCIENCES, INC. (ARTL) (CIK 0001621221) (ARTL) — Feb 3, 2020
ARTELO BIOSCIENCES, INC. (ARTL) (CIK 0001621221)
Date: Feb. 3, 2020 · CIK: 0001621221 · Accession: 0001640334-20-000182
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-235917
Letter
wordproof.doc
February 3, 2020
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549-3720
Attention: Katherine Bagley
Re:
Artelo Biosciences, Inc.
Registration Statement on Form S-3
Filed on January 15, 2020
File No. 333-235917
Acceleration Request Requested Date: February 3, 2020
Requested Time: 2:00 P.M. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Artelo Biosciences, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-235917) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable, or at such later time as the Company or its counsel may request via telephone call to the staff of the Division of Corporation Finance (the “Staff”) of the Securities and Exchange Commission (the “Commission”). The Company hereby authorizes Thomas Hornish of Wilson Sonsini Goodrich & Rosati, Professional Corporation, counsel for the Company, to make such request on the Company’s behalf.
The Company acknowledges that should the Commission or its Staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing. In addition, the Company acknowledges that the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing. Finally, the Company acknowledges that it may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
The Company requests that it be notified of the effectiveness of the Registration Statement by telephone to Thomas Hornish of Wilson Sonsini Goodrich & Rosati, Professional Corporation at (858) 350-2392 or via email at thornish@wsgr.com. If notice of effectiveness is given by telephone, please also provide a copy of the Commission’s order declaring the Registration Statement effective to Thomas Hornish via facsimile at (858) 350-2399.
Securities and Exchange Commission
Re: Artelo Biosciences, Inc.
February 3, 2020
Page 2
Please direct any questions or comments regarding this acceleration request to Thomas Hornish at (858) 350-2392.
Sincerely,
ARTELO BIOSCIENCES, INC.
Show Raw Text
CORRESP 1 filename1.htm wordproof.doc February 3, 2020 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549-3720 Attention: Katherine Bagley Re: Artelo Biosciences, Inc. Registration Statement on Form S-3 Filed on January 15, 2020 File No. 333-235917 Acceleration Request Requested Date: February 3, 2020 Requested Time: 2:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Artelo Biosciences, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-235917) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable, or at such later time as the Company or its counsel may request via telephone call to the staff of the Division of Corporation Finance (the “Staff”) of the Securities and Exchange Commission (the “Commission”). The Company hereby authorizes Thomas Hornish of Wilson Sonsini Goodrich & Rosati, Professional Corporation, counsel for the Company, to make such request on the Company’s behalf. The Company acknowledges that should the Commission or its Staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing. In addition, the Company acknowledges that the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing. Finally, the Company acknowledges that it may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. The Company requests that it be notified of the effectiveness of the Registration Statement by telephone to Thomas Hornish of Wilson Sonsini Goodrich & Rosati, Professional Corporation at (858) 350-2392 or via email at thornish@wsgr.com. If notice of effectiveness is given by telephone, please also provide a copy of the Commission’s order declaring the Registration Statement effective to Thomas Hornish via facsimile at (858) 350-2399. Securities and Exchange Commission Re: Artelo Biosciences, Inc. February 3, 2020 Page 2 Please direct any questions or comments regarding this acceleration request to Thomas Hornish at (858) 350-2392. Sincerely, ARTELO BIOSCIENCES, INC. By: /s/ Gregory D. Gorgas Gregory D. Gorgas President and Chief Executive Officer cc: Thomas E. Hornish, Esq. Mahnaz Daruwalla, Esq. Wilson Sonsini Goodrich & Rosati, Professional Corporation